These are top 10 stocks traded on the Robinhood UK platform in July
atai Life Sciences N.V. (NASDAQ:ATAI), a biopharmaceutical company, announced the results of its annual general meeting held on May 15, 2025. The meeting saw the approval of several key proposals, including the adoption of the company’s annual accounts for fiscal year 2024 and the appointment of Deloitte & Touche LLP and Deloitte Accountants B.V. as external auditors for fiscal year 2025.
Shareholders voted in favor of releasing members of atai’s supervisory and management boards from liability for their duties during fiscal year 2024. John Hoffman was appointed as a supervisory director until the 2028 annual general meeting, and Dr. Srinivas Rao and Anne Johnson were appointed as managing directors. However, following the meeting and the approval of all proposals, Anne Johnson will not serve on the board of directors.
The company also received approval for amendments to its articles of association, which included revising the governance model to a one-tier board with executive and non-executive directors, removing certain limitations related to the company’s German tax residency, and removing the supermajority requirement for amending the articles of association.
The compensation policy suitable for a unitary board of directors was adopted, contingent upon the approval of the amendments to the articles of association. Additionally, the management board was authorized to issue shares, limit, and exclude pre-emption rights, and acquire shares in the company’s capital.
The meeting’s outcomes are expected to streamline atai Life Sciences’ governance structure and provide greater flexibility for future operations. The company’s management board emphasized its commitment to advancing atai’s mission and maximizing shareholder value.
The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.